Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
IMA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 04, 2026
Report Source: 2026 1st Quarter Report
ImageneBio Inc. Stock Analysis IMA
United States Health Care Micro Cap Report: ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Read More ImageneBio Inc (IMA) Chart
Key Statistics of ImageneBio Inc (IMA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$5.90Volume
9188.00P/E Ratio (TTM)
-52 Week Range
Market Cap
61.74MAvg. Volume
16.38KDividend Yield
-Financial Metrics & Statements of ImageneBio Inc (IMA)
FAQ's for ImageneBio Inc (IMA)
- According to Musaffa’s Shariah screening methodology, ImageneBio Inc (IMA) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ImageneBio Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in ImageneBio Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of ImageneBio Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of ImageneBio Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of ImageneBio Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.